Business Wire

Secure Access is Broken. Fyde Enterprise Fixes It.

4.11.2019 14:00:00 EET | Business Wire | Press release

Share

Fyde, the new standard for Zero Trust, today announced Fyde Enterprise, a continuous, adaptive secure access solution that mitigates risk while protecting privacy and increasing performance. As digital transformation and the cloud transform the way we work and access apps, the disappearance of the traditional corporate perimeter creates new security risks and compliance challenges that break traditional solutions like VPNs. A powerful alternative to VPNs, Fyde Enterprise works on any infrastructure, any device, and with any application on a corporate network. Distributed businesses can now modernize remote access, enforce global security and access policies, and achieve seamless connectivity without compromising productivity.

Fyde, a first-time participant at Web Summit, is a featured startup and will be speaking on Centre Stage at the Breakout startups on November 4 at 5:00 pm and November 6 at 9:15 am. Fyde is also an exhibitor in the Beta Startup Programme on Tuesday, November 5.

Zero Trust for the Modern Enterprise

The Zero Trust paradigm assumes that all access is conditional and the network is always untrusted. Every interaction with the corporate network or cloud infrastructure must be granted contextual and conditional access based on continuous evaluation of device attributes (such as critical updates, security configuration and geographic location) and user identity (such as enforcing MFA or re-authentication) to ensure the highest levels of security.

Security teams must adapt to new requirements for the cloud, employee mobile devices, and evolving access dynamics associated with contractors, partners and remote employees. Fyde’s Zero Trust approach to secure access is driven by identity-aware access control and device-trust based security policies. Fyde enables secure, reliable and fast access to authorized apps and workloads on corporate networks and cloud infrastructure from any device, network, and location. Fyde also protects user identities from account takeover attacks.

“CISOs are frustrated by the failure of their traditional secure access solutions to deliver essential visibility and control over access to corporate resources, as well as to block emerging threats,” said Sinan Eren, Fyde CEO. “Fyde is built to address the security challenges created by the evolving threat landscape, while protecting employee privacy, boosting productivity, and ensuring compliance.”

Fyde Enterprise: The Onramp to Zero Trust

Fyde Enterprise is easy to deploy, monitor and manage. Security and IAM teams can sync with their user directory for seamless onboarding and deprovisioning of users and devices, monitor and log access requests and sessions via the Fyde Enterprise management console. Fyde Enterprise includes features for today’s complex IT environments, enabling security teams to deliver:

Zero Trust on any infrastructure or platform

  • Grant minimal privileged access to authorized apps without exposing the network
  • Work on Mobile or Desktop
  • Deploy on-premises or in hybrid or public cloud
  • Continuously verify users and devices

Global Security and Access Policies

  • Create robust access policies and gain visibility into who has access, to what and from where
  • Assign role-based and attribute-based policies

Upgraded performance and privacy

  • Eliminate latency via local inspection
  • Offer self-service remediation
  • Reduce IT Costs
  • Secure the data plane: Fyde does not have visibility into data.
  • Protect employee privacy. No personal data is shared with the company.

Pricing and availability

Fyde Enterprise is available today. Fyde is sold as an annual subscription with pricing starting at $10 per user per month. Enterprise bundles are available. To try Fyde today, visit Fyde.com/sign-up

About Fyde

Fyde is the new standard for Zero Trust secure access. An increasingly decentralized world is driving digital transformation and challenging the status quo. Fyde helps organizations mitigate risks while adapting to the new nature of work and IT, powering their journey to the Zero Trust Architecture. Our innovative approach is driven by patented technology that enables secure, reliable and fast access to any on-premises, cloud or hybrid app or workload. Fyde eliminates security risks associated with traditional VPN access, while protecting user identities from account takeover attacks. To learn more about Fyde, visit Fyde.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

U.S.
Dawn van Hoegaerden
Fyde
dawn@fyde.com
@dawnvanh

Portugal
Carla Silva
Fyde
carla@fyde.com

Fyde, Inc.
425 Sherman Ave.
Suite 220
Palo Alto CA 94306
USA
+1 650 275 2835

Fyde Portugal
Rua D. João IV, 429
4000-303 Porto
Portugal
+351 919 289 288

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level

Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye